Limani Perparim, Samaras Panagiotis, Lesurtel Mickael, Graf Rolf, DeOliveira Michelle L, Petrowsky Henrik, Clavien Pierre-Alain
Schweizerisches Hepato-Pancreato-Biliäres Zentrum und Departement Chirurgie, Universitätsspital Zürich.
Schweizerisches Hepato-Pancreato-Biliäres Zentrum und Klinik für Onkologie, Universitätsspital Zürich.
Praxis (Bern 1994). 2015 Apr 22;104(9):453-60. doi: 10.1024/1661-8157/a001990.
Pancreatic cancer is the seventh most common cancer in Switzerland associated with a dismal prognosis. Its natural course is fatal with a 3-year survival rate below 3%. Advances in diagnostic tools, tumor staging and multimodal treatment strategies resulted in an improved 5-year survival rate of over 20%. Patients presenting with pancreatic cancer significantly benefit from a multi-disciplinary treatment strategy in an experienced hepato-pancreato-biliary center. Following a comprehensive tumor staging, surgical resection associated with adjuvant chemotherapy is still the only curative therapy option. The role of neoadjuvant chemotherapy is currently investigated in clinical trials. Patients presenting with advanced pancreatic cancer not eligible for curative treatment might benefit from inclusion into innovative clinical trials with novel treatment concepts.
胰腺癌是瑞士第七大常见癌症，预后不佳。其自然病程是致命的，3年生存率低于3%。诊断工具、肿瘤分期和多模式治疗策略的进步使5年生存率提高到了20%以上。患有胰腺癌的患者在经验丰富的肝胰胆中心接受多学科治疗策略会显著受益。在进行全面的肿瘤分期后，手术切除联合辅助化疗仍然是唯一的治愈性治疗选择。新辅助化疗的作用目前正在临床试验中进行研究。患有无法进行治愈性治疗的晚期胰腺癌患者可能会受益于纳入具有新颖治疗理念的创新临床试验。
